News & Updates

Treatment with the Janus kinase (JAK) 1 inhibitor povorcitinib results in significant repigmentation of the body and face in adult patients with extensive nonsegmental vitiligo (NSV), with an acceptable safety profile, through 52 weeks, reports a phase II study.

Application of delgocitinib cream results in significant improvements in itch, pain, and quality of life (QoL) at week 16 in adults with moderate to severe chronic hand eczema (CHE), as shown in the pooled analysis of the phase III DELTA-1 and -2 trials.

Treatment with deucravacitinib demonstrates its superiority to placebo across several endpoints in patients with psoriatic arthritis (PsA) at week 16, according to the phase III POETYK PsA-2 study. Clinical responses have also persisted for up to a year.

Ritlecitinib 50 mg demonstrates clinically meaningful efficacy up to 36 months in individuals with alopecia areata (AA) in the phase IIb/III ALLEGRO and ongoing phase III ALLEGRO-LT trials.